肝纤维化是多种慢性肝病发展到肝硬化、肝癌的必经中间过程。但目前在肝纤维化的防治中仍然存在较多难点，且尚无肝纤维化防控的有效西药，因此阻断肝纤维化进展至肝硬化、肝癌的任务依然艰巨。长期实践证实，中医药对肝纤维化的预防及治疗均具有较好的效果，但是如何有效地提高中医治疗肝纤维化的疗效，使中医药在阻断肝纤维化甚至肝硬化、肝癌的发生发展方面更好地发挥优势，也是当前研究的重要课题。早在《黄帝内经》就提出“杂合以治”的治疗思想，从杂合以治的思想出发，整合中医不同疗法的优势，建立中医多方法、多靶点的肝纤维化治疗方案，对于提高肝纤维化的疗效具有重要意义。多维立体系列疗法在杂合以治的思想指导下，长期应用于阻断逆转肝纤维化，效果显著。

Liver fibrosis constitutes a critical intermediary phase in the advancement of numerous chronic liver diseases towards cirrhosis and hepatocellular carcinoma （HCC）. However， significant challenges remain in the prevention and treatment of liver fibrosis， especially in preventing its progression to cirrhosis and HCC. Unfortunately， there is currently no efficacious pharmacological intervention available for the prevention and management of liver fibrosis. Extensive longitudinal studies have substantiated the efficacy of Traditional Chinese Medicine （TCM） in the prevention and treatment of liver fibrosis. Enhancing the therapeutic efficacy of TCM in the treatment of liver fibrosis， as well as optimizing its potential to inhibit the onset and progression of liver fibrosis， cirrhosis， and HCC， continues to be a critical area of research. The therapeutic concept of "Combination Therapy with Diverse Methods and Prescriptions" was proposed as early as in "Huangdi Neijing". Building on this concept， integrating various TCM therapies to create a multi-method， multi-target treatment plan is crucial for enhancing liver fibrosis treatment efficacy. Guided by the therapeutic concept of "Combination Therapy with Diverse Methods and Prescriptions"， the multi-dimensional and systematic therapeutic approach has been consistently employed to inhibit and reverse liver fibrosis， yielding significant outcomes.